Targeting of albumin-embedded paclitaxel nanoparticles to tumors

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 5, Issue 1, 2009, Pages 73-82

  Karmali, Priya Prakash ^a   Kotamraju, Venkata Ramana ^a   Kastantin, Mark ^b   Black, Matthew ^b   Missirlis, Dimitris ^b   Tirrell, Matthew ^b   Ruoslahti, Erkki ^a  

^a BURNHAM INSTITUTE   (United States)

^b University of California   (United States)

Author keywords

Drug delivery; Peptides; Tumor markers; Tumor targeting; Tumor vessels

Indexed keywords

AMINES; BLOOD; BLOOD VESSELS; DRUG DELIVERY; NANOPARTICLES; ONCOLOGY; PEPTIDES; PROTEINS;

ALBUMIN NANOPARTICLES; HOMING PEPTIDES; HUMAN CANCERS; INHIBITION OF TUMOR GROWTHS; MIXED MICELLES; PACLITAXEL; RED BLOOD CELLS; SELF-ASSEMBLED; TUMOR MARKERS; TUMOR TARGETING; TUMOR TISSUES; TUMOR VESSELS;

TUMORS;

FIBRIN; NANOPARTICLE; PACLITAXEL; PHOSPHORUS 32;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; DRUG TUMOR LEVEL; DRUG UPTAKE; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; HUMAN; HUMAN CELL; INTERSTITIUM; MICELLE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR MODEL; TUMOR XENOGRAFT; VASCULAR TUMOR;

ALBUMINS; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; NANOPARTICLES; PACLITAXEL; PEPTIDES;

MUS;

EID: 59849110112     PISSN: 15499634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nano.2008.07.007     Document Type: Article

References (31)

1. Jain R.K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9 (1990) 253-266
2. Ferrara N., and Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5 (1999) 1359-1364
3. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
4. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer 2 (2002) 83-90
5. Arap W., Pasqualini R., and Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279 (1998) 377-380
6. Hoffman J.A., Giraudo E., Singh M., Zhang L., Inoue M., Porkka K., et al. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell 4 (2003) 383-391
7. Joyce J.A., Laakkonen P., Bernasconi M., Bergers G., Ruoslahti E., and Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell 4 (2003) 393-403
8. Laakkonen P., Porkka K., Hoffman J.A., and Ruoslahti E. A tumor-homing peptide with a targeting specificity related to lymphatic vessels. Nat Med 8 (2002) 751-755
9. Pilch J., Brown D.M., Komatsu M., Jarvinen T.A., Yang M., Peters D., et al. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc Natl Acad Sci U S A 103 (2006) 2800-2804
10. Ruoslahti E., Duza T., and Zhang L. Vascular homing peptides with cell-penetrating properties. Curr Pharm Des 11 (2005) 3655-3660
11. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L., et al. Biomimetic amplification of nanoparticle homing to tumors. Proc Natl Acad Sci U S A 104 (2007) 932-936
12. Zhang L., Giraudo E., Hoffman J.A., Hanahan D., and Ruoslahti E. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res 66 (2006) 5696-5706
13. Dvorak H.F., Senger D.R., Dvorak A.M., Harvey V.S., and McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 227 (1985) 1059-1061
14. Ghebrehiwet B., Lim B.L., Peerschke E.I., Willis A.C., and Reid K.B. Isolation, cDNA cloning, and overexpression of a 33-kD cell surface glycoprotein that binds to the globular "heads" of C1q. J Exp Med 179 (1994) 1809-1821
15. Fogal V., Zhang L., and Ruoslahti E. Mitochondrial/cell surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res 68 (2008) 7210-7218
16. Akerman M.E., Chan W.C., Laakkonen P., Bhatia S.N., and Ruoslahti E. Nanocrystal targeting in vivo. Proc Natl Acad Sci U S A 99 (2002) 12617-12621
17. von Maltzahn G., Ren Y., Park J.-H., Min D.-H., Kotamraju V.R., Jayakumar J., et al. In vivo tumor cell targeting with "click" nanoparticles. Bioconjug Chem 19 (2008) 1570-1578
18. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23 (2005) 7794-7803
19. Laakkonen P., Akerman M.E., Biliran H., Yang M., Ferrer F., Karpanen T., et al. Antitumor activity of a homing peptide that targets tumor lymphatics and tumor cells. Proc Natl Acad Sci U S A 101 (2004) 9381-9386
20. Desai N., Trieu V., Yao Z., Louie L., Ci S., Yang A., et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12 (2006) 1317-1324
21. Arleth L., Ashok B., Onyuksel H., Thiyagarajan P., Jacob J., and Hjelm R.P. Detailed structure of hairy mixed micelles formed by phosphatidylcholine and PEGylated phospholipids in aqueous media. Langmuir 21 (2005) 3279-3290
22. Tu R.S., and Tirrell M. Bottom-up design of biomimetic assemblies. Adv Drug Deliv Rev 56 (2004) 1537-1563
23. Rosenberg A.G.K., Studier F.W., McCormick M., Berg J., Novy R., and Mierendorf R. T7Select® Phage Display System: a powerful new protein display system based on bacteriophage T7. Innovations 6 (1996) 1-6. http://www.emdbiosciences.com/docs/NDIS/inno06-000.pdf Available at:
24. Park J.-H., von Maltzberg G., Zhang L., Schwartz M.P., Ruoslahti E., Bhatia S.N., et al. Magnetic iron oxide nanoworms for tumor targeting and imaging. Adv Mater 20 (2008) 1630-1635
25. Le Q.T., Denko N.C., and Giaccia A.J. Hypoxic gene expression and metastasis. Cancer Metastasis Rev 23 (2004) 293-310
26. Subarsky P., and Hill R.P. The hypoxic tumour microenvironment and metastatic progression. Clin Exp Metastasis 20 (2003) 237-250
27. Sullivan R., and Graham C.H. Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26 (2007) 319-331
28. Langel U. Cell-penetrating peptides: processes and applications (2002), CRC Press, Boca Raton (Fla)
29. Zorko M., and Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev 57 (2005) 529-545
30. Vives E. Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J Control Release 109 (2005) 77-85
31. Heldin C.H., Rubin K., Pietras K., and Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 4 (2004) 806-813